Breaking News on Supplements & Nutrition - EuropeUS edition

On your radar > Financial plays

Financial plays

Digging below the bottom lines of ingredients suppliers and brand behemoths. From the impact of the ongoing economic slowdown to the latest in merger and acquisition activity.

It would appear pharma giant Pfizer has gargantuan supplement ambitions as it buys Danish player, Ferrosan

Pfizer acquires Danish food supplements operation

Pfizer has acquired the consumer healthcare business of Danish firm Ferrosan for an undisclosed fee in what the pharma giant says, “is an excellent strategic fit that strengthens our presence...

Analysts: DuPont Danisco buy-out may end in fire sale

Analysts are saying Danisco could be carved up by its new owner DuPont, which they suggest is most interested in the Danish company’s enzymes for biofuels and that the food...

Lonza sees steady sales growth while profits boom

Lonza has revealed full year results showing sales gains that helped to drive strong profit growth, despite the impact of REACH and negative currency exchange rates.

Glanbia confirms outlook despite Irish economic woes

Glanbia has reiterated its strong outlook for full year profits despite the poor performance of its US cheese and Irish consumer businesses.

Lactalis pays €8.28m for stake in Spanish ingredients researcher

The Spanish subsidiary of French dairy giant Lactalis has paid €8.28m for 29.9 per cent of the ingredients research division of Spanish dairy group Ebro Foods, which produces the omega-3...

Will DuPont's Danisco purchase provoke other probiotic takeover activity?

DuPont’s Danisco buy boosts probiotics and could spur further acquisitions

DuPont’s €4.9bn acquisition of Danish probiotics and sweeteners specialist Danisco this week is vindication of the increasing economic viability of functional foods, according to analysts.

Omega-3 maker acquired by Atrium Innovations

Belgian omega-3 manufacturer Minami Nutrition has been acquired by Canadian supplement company Atrium Innovations for €5m in cash.

DSM's €24/share offer for Martek remains open until February 21, 2010

DSM’s Greenback formalises €829m Martek tender

Greenback Acquisition Corporation, a wholly-owned Royal DSM subsidiary, has begun the formal tender for Martek Biosciences, which DSM announced it was buying for €829m ($1.087bn) last month.

Chr Hansen's Health and Nutrition Division saw Q1 revenue jump 16 per cent

Chr. Hansen raises revenue forecast after strong first quarter

Danish bioscience firm Chr. Hansen is raising its revenue predictions by 11-13 per cent for 2010/11 after what it describes as “strong growth” in its first quarter from the September...

News in brief

EU approves BASF’s €3bn Cognis acquisition

The European Commission (EC) has approved BASF's acquisition of Cognis, with the takeover is expected to be finalised this month.

UK stock market regulation crucial to food prices, say economists

Regulating food speculation in the City of London is the lynchpin to preventing volatility over food prices, say economists, as parallel measures on both sides of the Atlantic will block...

DSM buys US biotech firm with carotenoid ambitions

DSM has acquired biotech firm Microbia in an undisclosed deal as the company expands its carotenoid operations.

Aker records first ever profit

Norwegian krill supplier Aker BioMarine has turned in its first-ever quarterly profit as European, US and Asian sales for the omega-3 source surged in the first half of 2010.

Nutra krill drives Aker towards profitability

Norwegian krill oil supplier Aker BioMarine expects to turn a profit for the first time in 2011 as its human nutrition business develops outside of the US.

Coke investment may force Innocent to grow up

Coca Cola has upped its stake in healthy smoothie maker, Innocent, to 58 per cent in a non-disclosed move one analyst said followed the gradual erosion of Innocent’s once vibrant...

Glanbia sale could clear way for nutritional acquisitions

Glanbia is expected to make acquisitions in the nutritional ingredients sector if the mooted sale of its Dairy Ireland business goes ahead.

Supplement weakness dampens Cognis nutrition sales

Cognis has reported a 6.8 per cent decline in nutritional and health product revenue for the first 9 months of 2009 as the European market weakens and supplement sales slump.

Exclusive interview

Naturex president: acquisition policy remains unchanged

Naturex president and chief executive officer, Jacques Dikansky, tells Shane Starling why in August the French botanicals giant bought Spanish supplier, Natraceutical Group, to double its size for the third...

DSM contracts suspended in China

DSM has said that it intends to look for new partners in China for its nutritional products and anti-infectives, after its contracts with North China Pharmaceutical Group Corporation (NCPC) were...

Naturex merger to double 2009 earnings

Naturex, the French-based botanicals giant that recently acquired the ingredients business of Spanish company, Natraceutical Group, will earn €185m in 2009 – up from its 2008 income of €93.2m, as...

ADM reports 83% profit decline; corn processing division battered

Archer Daniels Midland (ADM) has reported an 83 percent decline in net earnings for Q4 2009, and in corn processing increased profits from corn-based starches and sweeteners were buried by...

Nutrition division stars as DSM H1 profits plunge

Dutch life sciences giant, DSM, is feeling the effects of the recession with profits sliding 76 per cent, but its Nutrition division has bucked the trend to be the only...

Raisio Q2 results dip but not beyond expectation

Raisio, the Finnish ingredients supplier and owner of the Benecol plant stanol cholesterol-lowering range, reports lower sales and profits for the second quarter of 2009, drops the company said it...

Comment

Economic depression a stimulus for fresh business

The economic recession is biting across the globe, and bleeding casualties litter all industries, but now is not the time to cower. Those willing to spend may provoke a stimulation...

DSM turns record profit ahead of ‘uncertain’ year

“A year of stark contrasts” as DSM board chairman, Feike Sijbesma called it, has seen DSM turn a near €1bn profit but left the Dutch ingredients giant unable to make...